394 related articles for article (PubMed ID: 1279832)
1. Platelet factor XIII increases the fibrinolytic resistance of platelet-rich clots by accelerating the crosslinking of alpha 2-antiplasmin to fibrin.
Reed GL; Matsueda GR; Haber E
Thromb Haemost; 1992 Sep; 68(3):315-20. PubMed ID: 1279832
[TBL] [Abstract][Full Text] [Related]
2. Promotion of the crosslinking of fibrin and alpha 2-antiplasmin by platelets.
Hevessy Z; Haramura G; Boda Z; Udvardy M; Muszbek L
Thromb Haemost; 1996 Jan; 75(1):161-7. PubMed ID: 8713796
[TBL] [Abstract][Full Text] [Related]
3. Fibrin-fibrin and alpha 2-antiplasmin-fibrin cross-linking by platelet factor XIII increases the resistance of platelet clots to fibrinolysis.
Reed GL; Matsueda GR; Haber E
Trans Assoc Am Physicians; 1991; 104():21-8. PubMed ID: 1845147
[No Abstract] [Full Text] [Related]
4. Rapid dissociation of platelet-rich fibrin clots in vitro by a combination of plasminogen activators and antiplatelet agents.
Lam SC; Dieter JP; Strebel LC; Taylor TM; Muscolino G; Feinberg H; Le Breton GC
J Pharmacol Exp Ther; 1991 Dec; 259(3):1371-8. PubMed ID: 1762085
[TBL] [Abstract][Full Text] [Related]
5. Platelet-associated factor XIII in platelet activation, adhesion, and clot stabilization.
Devine DV; Bishop PD
Semin Thromb Hemost; 1996; 22(5):409-13. PubMed ID: 8989824
[TBL] [Abstract][Full Text] [Related]
6. Release of alpha 2-plasmin inhibitor from plasma fibrin clots by activated coagulation factor XIII. Its effect on fibrinolysis.
Mimuro J; Kimura S; Aoki N
J Clin Invest; 1986 Mar; 77(3):1006-13. PubMed ID: 2419360
[TBL] [Abstract][Full Text] [Related]
7. A monoclonal antibody against a peptide sequence of fibrinogen gamma chain acts as an inhibitor of factor XIII-mediated crosslinking of human fibrin.
Taubenfeld SM; Song Y; Sheng D; Ball EL; Matsueda GR
Thromb Haemost; 1995 Sep; 74(3):923-7. PubMed ID: 8571322
[TBL] [Abstract][Full Text] [Related]
8. Clot retraction increases clot resistance to fibrinolysis by condensing alpha 2-plasmin inhibitor crosslinked to fibrin.
Aoki N
Thromb Haemost; 1993 Aug; 70(2):376. PubMed ID: 8236154
[No Abstract] [Full Text] [Related]
9. Determinants of substrate specificity for factor XIII.
McDonagh J; Fukue H
Semin Thromb Hemost; 1996; 22(5):369-76. PubMed ID: 8989819
[TBL] [Abstract][Full Text] [Related]
10. Cross-linking of alpha 2-antiplasmin to fibrin is a key factor in regulating blood clot lysis: species differences.
van Giezen JJ; Minkema J; Bouma BN; Jansen JW
Blood Coagul Fibrinolysis; 1993 Dec; 4(6):869-75. PubMed ID: 7511944
[TBL] [Abstract][Full Text] [Related]
11. Rheological properties of fibrin clots. Effects of fibrinogen concentration, Factor XIII deficiency, and Factor XIII inhibition.
Glover CJ; McIntire LV; Brown CH; Natelson EA
J Lab Clin Med; 1975 Oct; 86(4):644-56. PubMed ID: 1176815
[TBL] [Abstract][Full Text] [Related]
12. Influence of factor XIIIa activity on human whole blood clot lysis in vitro.
Jansen JW; Haverkate F; Koopman J; Nieuwenhuis HK; Kluft C; Boschman TA
Thromb Haemost; 1987 Apr; 57(2):171-5. PubMed ID: 2440124
[TBL] [Abstract][Full Text] [Related]
13. Whole blood clots are more resistant to lysis than plasma clots--greater efficacy of rivaroxaban.
Varin R; Mirshahi S; Mirshahi P; Klein C; Jamshedov J; Chidiac J; Perzborn E; Mirshahi M; Soria C; Soria J
Thromb Res; 2013 Mar; 131(3):e100-9. PubMed ID: 23313382
[TBL] [Abstract][Full Text] [Related]
14. Compaction of fibrin clots reveals the antifibrinolytic effect of factor XIII.
Rijken DC; Abdul S; Malfliet JJ; Leebeek FW; Uitte de Willige S
J Thromb Haemost; 2016 Jul; 14(7):1453-61. PubMed ID: 27148673
[TBL] [Abstract][Full Text] [Related]
15. Defective alpha-polymerization in the conversion of fibrinogen Baltimore to fibrin.
Brown CH; Crowe MF
J Clin Invest; 1975 Jun; 55(6):1190-4. PubMed ID: 1133167
[TBL] [Abstract][Full Text] [Related]
16. Factor XIII cotreatment with hemostatic agents in hemophilia A increases fibrin α-chain crosslinking.
Beckman JD; Holle LA; Wolberg AS
J Thromb Haemost; 2018 Jan; 16(1):131-141. PubMed ID: 29080382
[TBL] [Abstract][Full Text] [Related]
17. RGDFAP: platelet aggregation inhibitory and profibrinolytic hybrid peptide (RGDF coupled with the carboxy terminal part of alpha 2-antiplasmin) enhances plasminogen binding to platelets.
Udvardy M; Schwartzott D; Jackson K; Posan E; Rak K; McKee PA
Blood Coagul Fibrinolysis; 1995 Jul; 6(5):481-5. PubMed ID: 8589217
[TBL] [Abstract][Full Text] [Related]
18. The roles of alpha 2-antiplasmin and plasminogen activator inhibitor 1 (PAI-1) in the inhibition of clot lysis.
Robbie LA; Booth NA; Croll AM; Bennett B
Thromb Haemost; 1993 Aug; 70(2):301-6. PubMed ID: 8236139
[TBL] [Abstract][Full Text] [Related]
19. Effect of crosslinking on the structure of solubilized fibrin degradation products in whole plasma.
Carroll RC; Lockhart MS; Taylor FB
J Lab Clin Med; 1984 May; 103(5):695-703. PubMed ID: 6232329
[TBL] [Abstract][Full Text] [Related]
20. Tissue plasminogen activator in human megakaryocytes and platelets: immunocytochemical localization, immunoblotting and zymographic analysis.
Jeanneau C; Sultan Y
Thromb Haemost; 1988 Jun; 59(3):529-34. PubMed ID: 3142087
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
